[{"data":1,"prerenderedAt":930},["ShallowReactive",2],{"content-route-/en/research/evidence/broad-candida-claims":3},{"state":4,"owner":4,"route":5,"locale":6,"template":7,"content":16,"projection":401,"alternates":921},"target","/en/research/evidence/broad-candida-claims","en-US",{"kind":8,"family":9,"sectionKeys":10},"evidence-map","guidance",[11,12,13,14,15],"claims","agreement-disagreement","changes","gaps","research",{"kind":8,"title":17,"description":18,"firstPublished":19,"evidenceAsOf":19,"lastUpdated":19,"changeNote":20,"firstLayer":21,"evidenceMap":51,"relations":113,"body":153},"Evidence map: broad Candida claims","Compare the exact evidence for broad Candida terminology, tests, diets, probiotics, biofilms, and \"die-off,\" with the populations and outcomes kept separate.","2026-07-15","Complete initial draft based on the Pathway B terminology, testing, diet and probiotic, biofilm and die-off, and US authority packs.",{"question":22,"answer":23,"keyPoints":24,"confidence":28,"applicability":31,"nextSteps":38},"What does the evidence say about broad Candida claims, tests, diets, probiotics, biofilms, and die-off?","There is no single evidence rating for all of these claims. Strong evidence distinguishes recognized, site-specific candidiasis from Candida presence and from invasive disease; moderate evidence does not support diagnosing a broad chronic syndrome from nonspecific symptoms, stool detection, invasive-disease assays used out of context, or a biofilm label. Diet, broad-symptom probiotic, biofilm-product, and Candida-specific die-off benefits remain unclear, while a small short-term probiotic signal applies only as an adjunct in a narrow VVC population.",[25,26,27],"The verdict changes with the exact population and outcome: SIFO is a narrow aspirate-defined research entity, VVC probiotic evidence concerns a defined vaginal condition, and neither can be transferred to a whole-body Candida claim.","A test can be useful for the condition and specimen it was designed for, but Candida detection or a commercial microbiome report does not by itself identify the cause of chronic nonspecific symptoms.","Worsening is not evidence that an antifungal, supplement, cleanse, or diet is working; product review, serious-reaction care, high-risk probiotic review, and crisis routing use separate observable safety rules.",{"summary":29,"rationale":30},"Strong or moderate confidence for the main terminology and invalid-extrapolation boundaries; early or unclear evidence for SIFO, diets, probiotics, marketed biofilm products, and Candida-specific die-off claims.","Current CDC and IDSA definitions, condition-specific diagnostic guidance, a systematic review of intestinal Candida, controlled and observational studies, systematic reviews of probiotics, and current biofilm and microbiome-testing evidence converge on the boundaries. Direct controlled evidence is absent or limited for many proposed interventions and broad outcomes, so those claims retain their own early or unclear ratings.",{"appliesTo":32,"excludes":35},[33,34],"Adolescents and adults checking whether chronic gastrointestinal or multisystem symptoms, a Candida-related test, or a marketed intervention establishes a broad Candida explanation.","People comparing claim-specific evidence before discussing testing, diet, probiotics, supplements, or persistent symptoms with a clinician.",[36,37],"People with a diagnosed site-specific or invasive Candida condition, whose testing and care follow that condition and clinical context.","People with a serious reaction, immediate medical emergency, suicidal thoughts, inability to stay safe, or acute emotional crisis, who should use the relevant urgent route now.",[39,43,47],{"label":40,"action":41,"route":42},"Check the exact term","Separate candidiasis, colonization, invasive candidiasis, SIFO, and broad overgrowth language before interpreting a claim.","/en/symptoms-conditions/candida-terms",{"label":44,"action":45,"route":46},"Prepare a clinical discussion","Bring the exact symptom pattern, timing, test method and report, products used, and response instead of treating one label as a diagnosis.","/en/tools/candida-claim-clinician-questions",{"label":48,"action":49,"route":50},"Review urgent routes","Use observable safety triggers rather than a Candida or die-off label to decide whether care is urgent.","/en/urgent-help",{"claimIds":52,"agreements":79,"disagreements":85,"gaps":88,"changeRoutes":94,"researchRoutes":95,"reassessmentTrigger":112},[53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78],"candidiasis-is-site-specific-disease-not-candida-presence","invasive-candidiasis-is-not-vernacular-systemic-candida","broad-candida-symptom-cluster-establishes-cause","nystatin-broad-candida-systemic-symptoms","sifo-is-narrow-clinical-research-entity","sifo-symptoms-alone-identify-overgrowth","sifo-antifungal-symptom-benefit","candida-testing-requires-condition-specific-method","candida-detection-alone-does-not-establish-vvc","stool-candida-detection-establishes-broad-syndrome","invasive-candida-assays-establish-broad-candida","dtc-microbiome-report-guides-candida-care","candida-test-review-prepares-clinical-evaluation","candida-diet-improves-broad-symptoms","candida-diet-eradicates-intestinal-candida","blood-type-diet-treats-candida","probiotics-adjunct-vvc-short-term","probiotics-prevent-vvc-recurrence","probiotic-replaces-antifungal-vvc","probiotics-treat-broad-candida-symptoms","candida-biofilms-have-defined-clinical-boundaries","biofilm-disruptor-improves-candida-outcomes","biofilm-label-establishes-broad-candida-cause","candida-treatment-causes-herxheimer-reaction","worsening-proves-candida-treatment-is-working","dieoff-label-alone-does-not-justify-crisis-routing",[80,81,82,83,84],"CDC and IDSA agree that recognized candidiasis is condition- and site-specific, while Candida can be present at nonsterile sites without establishing disease; invasive candidiasis is a distinct high-risk entity rather than a synonym for chronic nonspecific symptoms.","Current diagnostic authorities and the microbiome-testing consensus agree that the intended condition, specimen, method, risk context, and test limitations determine interpretation; organism detection or analyte measurement cannot be transferred automatically to a broad syndrome.","The intestinal-Candida review and current clinical definitions do not support a chronic multisystem syndrome diagnosed from a broad symptom cluster, and the controlled nystatin trial did not show a meaningful systemic or psychological advantage over placebo in its historical trial population.","Current sources do not establish that a restrictive Candida-labelled diet, a probiotic for broad symptoms, or a marketed biofilm-disrupting product improves a confirmed broad-Candida clinical outcome.","Candidiasis guidance and the die-off evidence review do not establish nonspecific worsening as evidence of fungal clearance or treatment benefit.",[86,87],"A 2017 Cochrane review found low-certainty short-term signals when probiotics were added to antifungals for uncomplicated VVC, while CDC says substantial evidence is absent and ISSVD concludes there is no demonstrated benefit; this disagreement does not establish monotherapy, recurrence prevention, a class effect, or benefit for broad symptoms.","A 2024 narrative review proposes a Candida die-off mechanism, while current candidiasis guidance does not recognize a Candida-specific Jarisch-Herxheimer syndrome and the review supplies no controlled incidence, diagnostic, or treatment-comparison evidence.",[89,90,91,92,93],"SIFO literature is small, uses selected specialist populations and aspirate culture, and does not yet establish a standardized diagnostic protocol, treatment benefit, duration, or relapse estimate.","The reviewed evidence contains no controlled human trial that confirms a broad Candida condition and shows that a named restrictive diet durably improves patient-important symptoms or eradicates clinically meaningful intestinal Candida.","Probiotic findings vary by strain, product, dose, route, population, co-intervention, and outcome; durable recurrence, monotherapy, broad-symptom benefit, cost, and higher-risk populations remain unresolved.","Most marketed biofilm-product evidence is laboratory or preclinical and does not establish symptom benefit, cure, recurrence prevention, or safe self-use.","No validated Candida-specific die-off incidence, diagnostic criteria, time course, prognostic rule, or evidence that worsening predicts benefit was identified.",[],[96,100,104,108],{"label":97,"description":98,"route":99},"SIFO aspirate and symptoms","A 150-person single-center referral study found aspirate-culture fungal overgrowth in some selected patients but similar symptom profiles with and without overgrowth; it is contextual and does not establish symptom diagnosis or treatment benefit.","/en/research/sifo-aspirate-symptoms-2013",{"label":101,"description":102,"route":103},"Nystatin and presumed systemic symptoms","A randomized crossover trial in 42 women found no meaningful nystatin advantage over placebo for systemic or psychological symptoms; it contradicts that intervention-specific historical claim without deciding every Candida treatment question.","/en/research/nystatin-candida-systemic-symptoms-1990",{"label":105,"description":106,"route":107},"Consumer microbiome test comparison","Identical standardized material produced substantial differences across seven services, supporting caution about analytical reproducibility; the study did not test Candida-specific accuracy or patient benefit.","/en/research/consumer-microbiome-test-comparison-2026",{"label":109,"description":110,"route":111},"Probiotics alongside antifungals for VVC","A Cochrane review found low-certainty short-term adjunct signals in uncomplicated VVC, but no established durable benefit and no applicability to recurrence, monotherapy, every product, or broad Candida symptoms.","/en/research/probiotics-for-vvc-cochrane-2017","Reassess this map when a new guideline, systematic review, controlled treatment or diagnostic-utility study, correction, or retraction changes any exact terminology, testing, diet, probiotic, biofilm, or die-off claim for its stated population and outcome, or by the next-review date.",[114,118,121,124,128,131,134,137,140,142,144,145,147,150],{"group":115,"route":116,"label":117},"parent","/en/treatments-evidence/candida-overgrowth-claim","The broad Candida overgrowth claim",{"group":119,"route":42,"label":120},"differential","Candida terminology",{"group":119,"route":122,"label":123},"/en/symptoms-conditions/sifo","SIFO orientation",{"group":125,"route":126,"label":127},"treatment","/en/treatments-evidence/candida-tests","Candida tests",{"group":125,"route":129,"label":130},"/en/treatments-evidence/candida-diet","Candida diet",{"group":125,"route":132,"label":133},"/en/treatments-evidence/probiotics-and-candida","Probiotics and Candida",{"group":125,"route":135,"label":136},"/en/treatments-evidence/candida-biofilms","Candida biofilms",{"group":125,"route":138,"label":139},"/en/treatments-evidence/candida-die-off","Candida die-off",{"group":15,"route":99,"label":141},"SIFO aspirate and symptoms study",{"group":15,"route":103,"label":143},"Nystatin and systemic symptoms trial",{"group":15,"route":107,"label":105},{"group":15,"route":111,"label":146},"Probiotics for VVC review",{"group":148,"route":46,"label":149},"tool","Candida claim clinician questions",{"group":151,"route":50,"label":152},"safety","Urgent help",{"type":154,"value":155,"toc":392},"minimark",[156,367,374,380,386],[157,158,160,165,222,226,272,276,322,326],"content-section",{"section-key":11,"title":159},"Exact claims and verdicts by population and outcome",[161,162,164],"h3",{"id":163},"terminology-and-causal-attribution","Terminology and causal attribution",[166,167,168,179,187,197,206],"ul",{},[169,170,171,175,176,178],"li",{},[172,173,174],"strong",{},"Recognized disease versus presence — adolescents and adults with a nonsterile-site Candida finding; correct distinction between colonization and site-specific disease:"," supported, ",[172,177,172],{}," evidence. Candida presence alone is not candidiasis.",[169,180,181,175,184,186],{},[172,182,183],{},"Invasive candidiasis versus vernacular “systemic Candida” — people using broad labels for chronic nonspecific symptoms; correct terminology:",[172,185,172],{}," evidence. Invasive candidiasis is a separate risk- and site-defined disease.",[169,188,189,192,193,196],{},[172,190,191],{},"Broad symptom cluster — immunocompetent people without established candidiasis; causal attribution of gastrointestinal or multisystem symptoms:"," not supported, ",[172,194,195],{},"moderate"," evidence.",[169,198,199,192,202,205],{},[172,200,201],{},"Nystatin in the historical trial population — 42 premenopausal women meeting proposed candidiasis-hypersensitivity criteria; systemic and psychological symptom improvement:",[172,203,204],{},"unclear"," evidence, specific to nystatin and that population.",[169,207,208,175,211,214,215,218,219,221],{},[172,209,210],{},"SIFO boundary — selected adults with otherwise-unexplained gastrointestinal symptoms; identification of an aspirate-defined research entity:",[172,212,213],{},"early"," evidence. Symptoms alone do not identify SIFO (",[172,216,217],{},"not supported, early","), and durable antifungal symptom benefit and eradication remain ",[172,220,204],{},".",[161,223,225],{"id":224},"tests","Tests",[166,227,228,235,243,250,257,265],{},[169,229,230,175,233,196],{},[172,231,232],{},"Condition-specific testing — people evaluated for vaginal, oral, esophageal, or invasive candidiasis; valid diagnosis or exclusion of that condition:",[172,234,172],{},[169,236,237,175,240,242],{},[172,238,239],{},"Candida in a vaginal sample — people with minimal, nonspecific, or absent symptoms; distinction between colonization and VVC:",[172,241,172],{}," evidence; detection alone does not establish VVC.",[169,244,245,192,248,196],{},[172,246,247],{},"Stool Candida — immunocompetent people with chronic nonspecific symptoms; causal diagnosis of a broad syndrome:",[172,249,195],{},[169,251,252,192,255,196],{},[172,253,254],{},"Invasive-disease assays used in stable low-risk outpatients — diagnosis of chronic broad overgrowth:",[172,256,195],{},[169,258,259,262,263,221],{},[172,260,261],{},"Commercial microbiome reports — chronic gastrointestinal or multisystem symptoms; actionable diagnosis and better patient outcomes from report-directed care:"," not enough evidence, ",[172,264,204],{},[169,266,267,175,270,196],{},[172,268,269],{},"Structured test review — people considering or holding a Candida-related report; better-informed selection and interpretation without treating it as a diagnosis:",[172,271,195],{},[161,273,275],{"id":274},"diet-and-probiotics","Diet and probiotics",[166,277,278,288,295,303],{},[169,279,280,262,283,285,286,221],{},[172,281,282],{},"Restrictive Candida-labelled diets — persistent nonspecific symptoms; improvement attributable to treating intestinal Candida:",[172,284,204],{},". Durable eradication or prevention of a defined Candida outcome is also ",[172,287,204],{},[169,289,290,262,293,221],{},[172,291,292],{},"ABO blood-type diet — people considering blood-group matching for suspected broad Candida illness; added Candida-specific benefit from matching:",[172,294,204],{},[169,296,297,300,301,196],{},[172,298,299],{},"Probiotic added to antifungal treatment — nonpregnant women with confirmed uncomplicated VVC, excluding recurrence and higher-risk groups; clinical or mycological cure within 5–14 days:"," may help, ",[172,302,213],{},[169,304,305,262,308,310,311,314,315,318,319,321],{},[172,306,307],{},"Probiotics for confirmed recurrent VVC — recurrence-free status at 3–6 months or longer:",[172,309,204],{},". ",[172,312,313],{},"Probiotic monotherapy"," for durable VVC cure and ",[172,316,317],{},"probiotics for broad Candida-attributed symptoms"," are also ",[172,320,204],{}," and concern different populations and outcomes.",[161,323,325],{"id":324},"biofilms-and-die-off","Biofilms and die-off",[166,327,328,335,342,349,356],{},[169,329,330,175,333,196],{},[172,331,332],{},"Candida biofilms in defined infection — people with clinically and microbiologically defined candidiasis, especially device-associated infection; clinical relevance without broad extrapolation:",[172,334,195],{},[169,336,337,192,340,196],{},[172,338,339],{},"Biofilm label for stable people with nonspecific symptoms — causal diagnosis of broad Candida illness:",[172,341,195],{},[169,343,344,262,347,221],{},[172,345,346],{},"Marketed biofilm-disrupting adjunct — confirmed mucosal candidiasis or presumed broad overgrowth; symptom improvement, cure, or recurrence reduction:",[172,348,204],{},[169,350,351,262,354,221],{},[172,352,353],{},"Candida-specific Jarisch-Herxheimer or “die-off” reaction — people starting an antifungal, supplement, or restrictive diet; validated incidence, criteria, time course, and mechanism:",[172,355,204],{},[169,357,358,192,361,363,364,366],{},[172,359,360],{},"Worsening during an intervention — proof of efficacy or reason to continue or intensify it:",[172,362,195],{}," evidence. A die-off label or worsening alone as a crisis predictor is ",[172,365,204],{},"; actual observable safety triggers control routing.",[157,368,370],{"section-key":12,"title":369},"Where sources agree and differ",[371,372,373],"p",{},"Authorities agree on the boundary between Candida presence, site-specific candidiasis, and invasive candidiasis, and on interpreting a diagnostic method only for its intended condition, specimen, and context. The intestinal-Candida review, current disease definitions, and the controlled nystatin trial do not support a broad symptom-list syndrome. Diet, broad-symptom probiotic, and marketed biofilm-product claims lack direct patient-important evidence. The principal disagreements are narrower: low-certainty short-term probiotic adjunct signals contrast with guideline conclusions that meaningful evidence is absent, and a narrative Candida die-off proposal is not established by current candidiasis guidance or controlled human evidence.",[157,375,377],{"section-key":13,"title":376},"Latest meaningful changes",[371,378,379],{},"No completed correction, retraction, guideline update, or evidence-change record currently changes a claim on this map. The four selected research summaries expose source contributions and limitations; none independently supplies or changes a canonical conclusion.",[157,381,383],{"section-key":14,"title":382},"Limitations and gaps",[371,384,385],{},"The evidence is uneven by question. Strong disease-definition and condition-specific-testing boundaries coexist with a small SIFO literature, old or indirect broad-syndrome evidence, heterogeneous and low-certainty probiotic trials, no controlled Candida-diet trial for the proposed broad outcomes, mostly preclinical biofilm-product research, and no validated Candida-specific die-off criteria. Test validity, intervention benefit, safety, and applicability must therefore remain separate rather than being compressed into one rating.",[157,387,389],{"section-key":15,"title":388},"Selected research and practical contribution",[371,390,391],{},"The selected summaries make four distinct contributions. The SIFO aspirate study is contextual and shows that symptoms did not discriminate culture groups. The placebo-controlled nystatin trial contradicts a historical systemic-symptom benefit claim for that drug and population. The 2026 commercial microbiome comparison supports caution about analytical reproducibility but did not study Candida diagnosis or patient outcomes. The Cochrane probiotic review supports only a low-certainty, short-term adjunct signal in uncomplicated VVC and does not establish durable, recurrence, monotherapy, product-class, or broad-symptom benefit. None of these summaries replaces the canonical claim records.",{"title":393,"searchDepth":394,"depth":394,"links":395},"",2,[396,398,399,400],{"id":163,"depth":397,"text":164},3,{"id":224,"depth":397,"text":225},{"id":274,"depth":397,"text":275},{"id":324,"depth":397,"text":325},{"sources":402,"claims":597,"safety":870},[403,411,415,423,431,439,447,455,459,465,472,480,486,493,499,506,513,520,527,534,540,547,551,558,565,572,577,583,590],{"sourceId":404,"title":405,"canonicalId":406,"canonicalUrl":407,"publisher":408,"sourceType":409,"publicationDate":410,"lastChecked":19},"cdc-candidiasis-basics-2024","Candidiasis Basics",null,"https://www.cdc.gov/candidiasis/about/index.html","US Centers for Disease Control and Prevention","regulator","2024-04-24",{"sourceId":412,"title":413,"canonicalId":406,"canonicalUrl":414,"publisher":408,"sourceType":409,"publicationDate":410,"lastChecked":19},"cdc-invasive-candidiasis-overview-2024","Clinical Overview of Invasive Candidiasis","https://www.cdc.gov/candidiasis/hcp/clinical-overview/",{"sourceId":416,"title":417,"canonicalId":418,"canonicalUrl":419,"publisher":420,"sourceType":421,"publicationDate":422,"lastChecked":19},"idsa-candidiasis-guideline-2016","Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","DOI:10.1093/cid/civ933","https://www.idsociety.org/practice-guideline/candidiasis/","Infectious Diseases Society of America","guideline","2016-02-15",{"sourceId":424,"title":425,"canonicalId":426,"canonicalUrl":427,"publisher":428,"sourceType":429,"publicationDate":430,"lastChecked":19},"jacobs-small-intestinal-overgrowth-2013","Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth","PMID:23574267; DOI:10.1111/apt.12304","https://pubmed.ncbi.nlm.nih.gov/23574267/","Alimentary Pharmacology & Therapeutics","observational-study","2013-06-01",{"sourceId":432,"title":433,"canonicalId":434,"canonicalUrl":435,"publisher":436,"sourceType":437,"publicationDate":438,"lastChecked":19},"erdogan-sifo-review-2015","Small intestinal fungal overgrowth","PMID:25786900; DOI:10.1007/s11894-015-0436-2","https://pubmed.ncbi.nlm.nih.gov/25786900/","Current Gastroenterology Reports","other","2015-04-01",{"sourceId":440,"title":441,"canonicalId":442,"canonicalUrl":443,"publisher":444,"sourceType":445,"publicationDate":446,"lastChecked":19},"dismukes-nystatin-candidiasis-hypersensitivity-1990","A randomized, double-blind trial of nystatin therapy for the candidiasis hypersensitivity syndrome","PMID:2247104; DOI:10.1056/NEJM199012203232501","https://pubmed.ncbi.nlm.nih.gov/2247104/","New England Journal of Medicine","randomized-trial","1990-12-20",{"sourceId":448,"title":449,"canonicalId":450,"canonicalUrl":451,"publisher":452,"sourceType":453,"publicationDate":454,"lastChecked":19},"lacour-intestinal-candida-systematic-review-2002","The pathogenetic significance of intestinal Candida colonization: a systematic review from an interdisciplinary and environmental medical point of view","PMID:12068745; DOI:10.1078/1438-4639-00159","https://pubmed.ncbi.nlm.nih.gov/12068745/","International Journal of Hygiene and Environmental Health","systematic-review","2002-05-01",{"sourceId":456,"title":457,"canonicalId":406,"canonicalUrl":458,"publisher":408,"sourceType":409,"publicationDate":410,"lastChecked":19},"cdc-candidiasis-testing-2024","Testing and Diagnosis for Candidiasis","https://www.cdc.gov/candidiasis/testing/index.html",{"sourceId":460,"title":461,"canonicalId":406,"canonicalUrl":462,"publisher":463,"sourceType":409,"publicationDate":464,"lastChecked":19},"fda-direct-to-consumer-tests-2019","Direct-to-Consumer Tests","https://www.fda.gov/medical-devices/in-vitro-diagnostics/direct-consumer-tests","US Food and Drug Administration","2019-12-20",{"sourceId":466,"title":467,"canonicalId":468,"canonicalUrl":469,"publisher":470,"sourceType":421,"publicationDate":471,"lastChecked":19},"porcari-microbiome-testing-consensus-2025","International consensus statement on microbiome testing in clinical practice","doi:10.1016/S2468-1253(24)00311-X","https://pubmed.ncbi.nlm.nih.gov/39647502/","The Lancet Gastroenterology & Hepatology","2025-02-01",{"sourceId":473,"title":474,"canonicalId":475,"canonicalUrl":476,"publisher":477,"sourceType":478,"publicationDate":479,"lastChecked":19},"servetas-dtc-microbiome-performance-2026","Evaluating the analytical performance of direct-to-consumer gut microbiome testing services","doi:10.1038/s42003-025-09301-3","https://pubmed.ncbi.nlm.nih.gov/41748906/","Communications Biology","laboratory-study","2026-02-26",{"sourceId":481,"title":482,"canonicalId":483,"canonicalUrl":484,"publisher":408,"sourceType":421,"publicationDate":485,"lastChecked":19},"cdc-sti-vvc-2021","Sexually Transmitted Infections Treatment Guidelines, 2021: Vulvovaginal Candidiasis","doi:10.15585/mmwr.rr7004a1","https://www.cdc.gov/std/treatment-guidelines/candidiasis.htm","2021-07-23",{"sourceId":487,"title":488,"canonicalId":489,"canonicalUrl":490,"publisher":491,"sourceType":421,"publicationDate":492,"lastChecked":19},"issvd-vaginitis-recommendations-2023","International Society for the Study of Vulvovaginal Disease Recommendations for the Diagnosis and Treatment of Vaginitis","doi:10.59153/adm.rdtv.001","https://www.issvd.org/resources/recommendations-for-the-diagnosis-and-treatment-of-vaginitis","International Society for the Study of Vulvovaginal Disease","2023-03-01",{"sourceId":494,"title":495,"canonicalId":406,"canonicalUrl":496,"publisher":497,"sourceType":437,"publicationDate":498,"lastChecked":19},"mayo-candida-cleanse-diet-2025","Candida cleanse diet: What does it treat?","https://www.mayoclinic.org/healthy-lifestyle/consumer-health/expert-answers/candida-cleanse/faq-20058174","Mayo Clinic","2025-06-28",{"sourceId":500,"title":501,"canonicalId":502,"canonicalUrl":503,"publisher":504,"sourceType":453,"publicationDate":505,"lastChecked":19},"cusack-blood-type-diets-review-2013","Blood type diets lack supporting evidence: a systematic review","PMID:23697707; DOI:10.3945/ajcn.113.058693","https://pubmed.ncbi.nlm.nih.gov/23697707/","The American Journal of Clinical Nutrition","2013-07-01",{"sourceId":507,"title":508,"canonicalId":509,"canonicalUrl":510,"publisher":511,"sourceType":421,"publicationDate":512,"lastChecked":19},"marco-fermented-foods-consensus-2021","The International Scientific Association for Probiotics and Prebiotics consensus statement on fermented foods","PMID:33398112; DOI:10.1038/s41575-020-00390-5","https://pmc.ncbi.nlm.nih.gov/articles/PMC7925329/","Nature Reviews Gastroenterology & Hepatology","2021-01-04",{"sourceId":514,"title":515,"canonicalId":516,"canonicalUrl":517,"publisher":518,"sourceType":453,"publicationDate":519,"lastChecked":19},"xie-probiotics-vvc-cochrane-2017","Probiotics for vulvovaginal candidiasis in non-pregnant women","CD010496; DOI:10.1002/14651858.CD010496.pub2","https://www.cochrane.org/evidence/CD010496_probiotics-vulvovaginal-candidiasis-non-pregnant-women","Cochrane Database of Systematic Reviews","2017-11-23",{"sourceId":521,"title":522,"canonicalId":523,"canonicalUrl":524,"publisher":525,"sourceType":453,"publicationDate":526,"lastChecked":19},"zahedifard-probiotics-vvc-review-2023","The Role of Probiotics in the Treatment of Vulvovaginal Candidiasis: A Systematic Review and Meta-Analysis","PMID:38784519; DOI:10.4314/ejhs.v33i5.18","https://pmc.ncbi.nlm.nih.gov/articles/PMC11111202/","Ethiopian Journal of Health Sciences","2023-09-01",{"sourceId":528,"title":529,"canonicalId":530,"canonicalUrl":531,"publisher":532,"sourceType":445,"publicationDate":533,"lastChecked":19},"pane-lf5-vvc-trial-2024","Efficacy of Limosilactobacillus fermentum in the management of vulvovaginal candidiasis: comparative analysis with topical miconazole in a single-blind randomized clinical trial","PMID:39149209; DOI:10.3389/fmicb.2024.1428590","https://pmc.ncbi.nlm.nih.gov/articles/PMC11324542/","Frontiers in Microbiology","2024-08-01",{"sourceId":535,"title":536,"canonicalId":537,"canonicalUrl":538,"publisher":408,"sourceType":421,"publicationDate":539,"lastChecked":19},"cdc-catheter-biofilm-pathogenesis-2024","Background Information: Pathogenesis — Guidelines for the Prevention of Intravascular Catheter-Related Infections","CDC catheter guideline pathogenesis","https://www.cdc.gov/infection-control/hcp/intravascular-catheter-related-infection/pathogenesis.html","2011-01-01",{"sourceId":541,"title":542,"canonicalId":543,"canonicalUrl":544,"publisher":545,"sourceType":437,"publicationDate":546,"lastChecked":19},"tuan-natural-candida-biofilm-review-2026","Natural-Compound Adjuvants Dismantle Candida Biofilms: Mechanisms, Design Rules, and Biofilm-Aware Pharmacology","PMID:41524898; DOI:10.1007/s00284-025-04713-0","https://pmc.ncbi.nlm.nih.gov/articles/PMC12795885/","Current Microbiology","2026-01-12",{"sourceId":548,"title":549,"canonicalId":483,"canonicalUrl":550,"publisher":408,"sourceType":421,"publicationDate":485,"lastChecked":19},"cdc-syphilis-herxheimer-2024","Syphilis — STI Treatment Guidelines: Jarisch-Herxheimer Reaction","https://www.cdc.gov/std/treatment-guidelines/syphilis.htm",{"sourceId":552,"title":553,"canonicalId":554,"canonicalUrl":555,"publisher":556,"sourceType":437,"publicationDate":557,"lastChecked":19},"jaiswal-candida-dieoff-review-2024","Candida die-off: Adverse effect and neutralization with phytotherapy approaches","PMID:38072320; DOI:10.1016/j.toxicon.2023.107555","https://pubmed.ncbi.nlm.nih.gov/38072320/","Toxicon","2024-01-01",{"sourceId":559,"title":560,"canonicalId":561,"canonicalUrl":562,"publisher":563,"sourceType":437,"publicationDate":564,"lastChecked":19},"psychosocial-recurrent-urogenital-review-2023","Psychosocial impact of recurrent urogenital infections: a review","doi:10.1177/17455057231216537","https://pubmed.ncbi.nlm.nih.gov/38099456/","SAGE Publications","2023-01-01",{"sourceId":566,"title":567,"canonicalId":568,"canonicalUrl":569,"publisher":570,"sourceType":409,"publicationDate":571,"lastChecked":19},"fda-dietary-supplements-2022","FDA 101: Dietary Supplements","FDA consumer update: FDA 101 Dietary Supplements","https://www.fda.gov/consumers/consumer-updates/fda-101-dietary-supplements","U.S. Food and Drug Administration","2022-06-02",{"sourceId":573,"title":574,"canonicalId":575,"canonicalUrl":576,"publisher":570,"sourceType":409,"publicationDate":571,"lastChecked":19},"fda-mixing-supplements-medications-2022","Mixing Medications and Dietary Supplements Can Endanger Your Health","FDA consumer update: mixing medications and dietary supplements","https://www.fda.gov/consumers/consumer-updates/mixing-medications-and-dietary-supplements-can-endanger-your-health",{"sourceId":578,"title":579,"canonicalId":580,"canonicalUrl":581,"publisher":570,"sourceType":409,"publicationDate":582,"lastChecked":19},"fda-supplement-problem-reporting-2025","How to Report a Problem with Dietary Supplements","FDA dietary-supplement adverse-event reporting page","https://www.fda.gov/food/dietary-supplements/how-report-problem-dietary-supplements","2025-03-13",{"sourceId":584,"title":585,"canonicalId":586,"canonicalUrl":587,"publisher":588,"sourceType":437,"publicationDate":589,"lastChecked":19},"nih-ods-probiotics-2025","Probiotics: Fact Sheet for Health Professionals","NIH Office of Dietary Supplements probiotics health-professional fact sheet","https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/","National Institutes of Health Office of Dietary Supplements","2025-03-25",{"sourceId":591,"title":592,"canonicalId":593,"canonicalUrl":594,"publisher":592,"sourceType":595,"publicationDate":596,"lastChecked":19},"988-lifeline-us-2022","988 Suicide & Crisis Lifeline","US three-digit crisis service 988","https://988lifeline.org/","official-care-service","2022-07-16",[598,611,621,636,644,654,663,676,685,695,707,717,728,739,748,757,766,778,789,800,810,820,829,840,850,861],{"claimId":53,"exactClaim":599,"outcome":600,"population":601,"verdict":602,"evidenceLevel":172,"rationale":603,"safetyStatus":604,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":606,"sources":607},"Candidiasis names disease caused by Candida at a defined body site; the presence of Candida on skin or in the mouth, gastrointestinal tract, or vagina without compatible disease does not itself establish candidiasis.","correct distinction between recognized site-specific candidiasis and asymptomatic Candida carriage or colonization","adolescents and adults encountering Candida terminology or a Candida finding from a nonsterile body site","supported","CDC describes Candida as normally present at several body sites and candidiasis as infection when it causes site-dependent disease. CDC and IDSA separately describe gastrointestinal, skin, and respiratory colonization and do not equate a nonsterile-site finding with invasive or mucosal disease.","usual-cautions","active",[],[608,609,610],{"title":405,"canonicalId":406,"canonicalUrl":407,"publisher":408,"sourceType":409,"publicationDate":410,"lastChecked":19},{"title":413,"canonicalId":406,"canonicalUrl":414,"publisher":408,"sourceType":409,"publicationDate":410,"lastChecked":19},{"title":417,"canonicalId":418,"canonicalUrl":419,"publisher":420,"sourceType":421,"publicationDate":422,"lastChecked":19},{"claimId":54,"exactClaim":612,"outcome":613,"population":614,"verdict":602,"evidenceLevel":172,"rationale":615,"safetyStatus":604,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":616,"sources":617},"Recognized invasive candidiasis is infection of the bloodstream or normally sterile internal sites in high-risk clinical populations; it is not a synonym for a self-attributed chronic multisystem symptom pattern called 'systemic Candida' or 'whole-body Candida overgrowth.'","accurate separation of invasive candidiasis from vernacular broad-overgrowth labels","adolescents and adults using broad Candida terminology for chronic gastrointestinal, fatigue, cognitive, mood, skin, or other nonspecific symptoms","CDC and IDSA define invasive candidiasis by invasive disease entities, risk context, cultures, and affected sterile sites. Their definitions do not map nonspecific chronic symptom lists in otherwise stable community populations to invasive candidiasis. This terminology boundary does not rule out a person's symptoms; it stops the invasive-disease label from being inferred from them.",[],[618,619,620],{"title":405,"canonicalId":406,"canonicalUrl":407,"publisher":408,"sourceType":409,"publicationDate":410,"lastChecked":19},{"title":413,"canonicalId":406,"canonicalUrl":414,"publisher":408,"sourceType":409,"publicationDate":410,"lastChecked":19},{"title":417,"canonicalId":418,"canonicalUrl":419,"publisher":420,"sourceType":421,"publicationDate":422,"lastChecked":19},{"claimId":55,"exactClaim":622,"outcome":623,"population":624,"verdict":625,"evidenceLevel":195,"rationale":626,"safetyStatus":604,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":627,"sources":628},"A broad cluster of nonspecific symptoms such as fatigue, bloating, altered bowel habits, concentration difficulty, mood symptoms, cravings, or skin complaints establishes intestinal Candida overgrowth as their shared cause.","valid causal attribution of a nonspecific multisystem symptom cluster to intestinal Candida overgrowth","immunocompetent adolescents and adults with chronic gastrointestinal and/or extraintestinal symptoms but without established site-specific or invasive candidiasis","not-supported","A systematic review of 96 eligible citations found intestinal Candida colonization common in healthy immunocompetent adults and found neither epidemiologic nor therapeutic evidence for a Candida or Candida-hypersensitivity syndrome. Current CDC and IDSA disease definitions do not recognize a symptom-list diagnosis of systemic or intestinal candidiasis. The controlled nystatin trial in women meeting proposed candidiasis-hypersensitivity criteria found no meaningful advantage over placebo for systemic or psychological symptoms. Early SIFO studies concern a narrower, selected gastrointestinal population assessed by small-bowel aspirate and cannot validate a broad multisystem syndrome. Plausible alternatives depend on the symptom pattern and include functional gastrointestinal disorders, medication effects, dietary intolerance, endocrine or hematologic disease, dermatologic conditions, sleep or mood disorders, and other infections; the attribution should stop and pivot to evaluation of the actual symptoms when a recognized Candida condition has not been established.",[],[629,630,631,632,633,634,635],{"title":449,"canonicalId":450,"canonicalUrl":451,"publisher":452,"sourceType":453,"publicationDate":454,"lastChecked":19},{"title":405,"canonicalId":406,"canonicalUrl":407,"publisher":408,"sourceType":409,"publicationDate":410,"lastChecked":19},{"title":413,"canonicalId":406,"canonicalUrl":414,"publisher":408,"sourceType":409,"publicationDate":410,"lastChecked":19},{"title":417,"canonicalId":418,"canonicalUrl":419,"publisher":420,"sourceType":421,"publicationDate":422,"lastChecked":19},{"title":441,"canonicalId":442,"canonicalUrl":443,"publisher":444,"sourceType":445,"publicationDate":446,"lastChecked":19},{"title":425,"canonicalId":426,"canonicalUrl":427,"publisher":428,"sourceType":429,"publicationDate":430,"lastChecked":19},{"title":433,"canonicalId":434,"canonicalUrl":435,"publisher":436,"sourceType":437,"publicationDate":438,"lastChecked":19},{"claimId":56,"exactClaim":637,"outcome":638,"population":639,"verdict":625,"evidenceLevel":204,"rationale":640,"safetyStatus":604,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":641,"sources":642},"Oral nystatin improves systemic or psychological symptoms more than placebo in women meeting proposed criteria for candidiasis hypersensitivity syndrome.","change in systemic symptom scores and standardized psychological symptom or distress measures","adult women with recurrent or persistent vaginal Candida history and systemic symptoms who met the trial's proposed candidiasis-hypersensitivity criteria, excluding invasive disease and major immunocompromising conditions","In the randomized double-blind crossover trial, systemic symptoms improved similarly with active nystatin and placebo (25% versus 23%; between-group difference 2%, 95% CI -3% to 7%), and psychological outcomes did not differ. The result directly addresses this drug and trial-defined population, not every proposed Candida intervention or every cause of the participants' symptoms.",[],[643],{"title":441,"canonicalId":442,"canonicalUrl":443,"publisher":444,"sourceType":445,"publicationDate":446,"lastChecked":19},{"claimId":57,"exactClaim":645,"outcome":646,"population":647,"verdict":602,"evidenceLevel":213,"rationale":648,"safetyStatus":604,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":649,"sources":650},"Small intestinal fungal overgrowth (SIFO) is a narrow clinical-research label for excessive fungal growth detected in small-intestinal aspirate in a person with gastrointestinal symptoms; it is not interchangeable with normal gut Candida carriage, invasive candidiasis, or a broad multisystem 'Candida overgrowth' syndrome.","correct identification of the population, sampling site, and disease boundaries represented by the term SIFO","adults with persistent otherwise-unexplained gastrointestinal symptoms considered for specialist small-intestinal evaluation","The 2013 single-center study and 2015 clinical review consistently use SIFO for fungal growth from duodenal or small-intestinal aspirate in selected symptomatic patients. The literature is small, largely from one investigator group, and lacks a standardized diagnostic protocol, so this supports a terminology boundary rather than a mature broadly applicable diagnosis.",[],[651,652,653],{"title":425,"canonicalId":426,"canonicalUrl":427,"publisher":428,"sourceType":429,"publicationDate":430,"lastChecked":19},{"title":433,"canonicalId":434,"canonicalUrl":435,"publisher":436,"sourceType":437,"publicationDate":438,"lastChecked":19},{"title":413,"canonicalId":406,"canonicalUrl":414,"publisher":408,"sourceType":409,"publicationDate":410,"lastChecked":19},{"claimId":58,"exactClaim":655,"outcome":656,"population":657,"verdict":625,"evidenceLevel":213,"rationale":658,"safetyStatus":604,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":659,"sources":660},"Bloating, belching, indigestion, nausea, gas, diarrhea, or abdominal discomfort alone can identify which adults with unexplained gastrointestinal symptoms have SIFO.","diagnostic discrimination between SIFO, mixed bacterial/fungal overgrowth, and no cultured small-intestinal overgrowth based on symptoms alone","adults with persistent gastrointestinal complaints after unrevealing routine endoscopic or radiologic evaluation","In the 150-person single-center observational study, symptom profiles were similar with and without cultured bacterial or fungal overgrowth. The 2015 review likewise describes common symptoms as nonspecific. Symptoms therefore orient further evaluation but do not establish SIFO; alternatives include functional gastrointestinal disorders, bacterial overgrowth, motility disorders, medication effects, dietary intolerance, and other gastrointestinal disease.",[],[661,662],{"title":425,"canonicalId":426,"canonicalUrl":427,"publisher":428,"sourceType":429,"publicationDate":430,"lastChecked":19},{"title":433,"canonicalId":434,"canonicalUrl":435,"publisher":436,"sourceType":437,"publicationDate":438,"lastChecked":19},{"claimId":59,"exactClaim":664,"outcome":665,"population":666,"verdict":667,"evidenceLevel":204,"rationale":668,"safetyStatus":669,"evidenceAsOf":19,"lastUpdated":19,"status":670,"changeHistory":671,"sources":672},"Antifungal treatment produces durable symptom improvement and eradicates excessive small-intestinal fungal growth in immunocompetent adults with aspirate-defined SIFO.","durable improvement in gastrointestinal symptoms and confirmed eradication on repeat small-intestinal aspirate culture","immunocompetent adults with persistent gastrointestinal symptoms and SIFO defined by fungal growth from a small-intestinal aspirate","not-enough-evidence","The available clinical review states that whether eradication or treatment resolves symptoms remains unclear and that evidence for eradication is lacking. The key observational study evaluated association and diagnostic discrimination rather than comparative treatment effectiveness. No current guideline or controlled treatment synthesis identified in the final search resolves benefit, duration, relapse, or patient selection.","elevated-risk","blocked",[],[673,674,675],{"title":425,"canonicalId":426,"canonicalUrl":427,"publisher":428,"sourceType":429,"publicationDate":430,"lastChecked":19},{"title":433,"canonicalId":434,"canonicalUrl":435,"publisher":436,"sourceType":437,"publicationDate":438,"lastChecked":19},{"title":417,"canonicalId":418,"canonicalUrl":419,"publisher":420,"sourceType":421,"publicationDate":422,"lastChecked":19},{"claimId":60,"exactClaim":677,"outcome":678,"population":679,"verdict":602,"evidenceLevel":172,"rationale":680,"safetyStatus":604,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":681,"sources":682},"There is no single Candida test that establishes every form of candidiasis; a diagnostically useful method and sample must match the suspected body site or invasive-disease setting and be interpreted with the clinical findings.","valid diagnosis or exclusion of the specific suspected form of candidiasis","adolescents and adults being evaluated for possible vaginal, oral or throat, esophageal, or invasive candidiasis","Current CDC diagnostic guidance assigns different examinations, specimen sites, microscopy, culture, endoscopy, and blood or infected-site testing to different Candida conditions. IDSA likewise treats culture and nonculture assays as condition-dependent tools and requires assay limitations, invasive-disease type, risk, and clinical setting to be considered. A result can contribute to the defined diagnosis for which the test was validated; it cannot establish unrelated Candida explanations across body sites, and negative blood culture alone does not exclude every deep-seated invasive infection because sensitivity is limited.",[],[683,684],{"title":457,"canonicalId":406,"canonicalUrl":458,"publisher":408,"sourceType":409,"publicationDate":410,"lastChecked":19},{"title":417,"canonicalId":418,"canonicalUrl":419,"publisher":420,"sourceType":421,"publicationDate":422,"lastChecked":19},{"claimId":61,"exactClaim":686,"outcome":687,"population":688,"verdict":602,"evidenceLevel":172,"rationale":689,"safetyStatus":604,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":690,"sources":691},"Detecting Candida in a vaginal sample without compatible symptoms and signs does not by itself establish symptomatic vulvovaginal candidiasis because asymptomatic colonization occurs.","distinction between asymptomatic Candida colonization and symptomatic vulvovaginal candidiasis","adolescents and adults with Candida detected in a vaginal sample, including those with minimal, nonspecific, or absent symptoms","CDC diagnostic guidance and the ISSVD guideline explicitly distinguish Candida detection or positive culture from symptomatic infection and do not treat asymptomatic detection as proof of disease.",[],[692,693,694],{"title":482,"canonicalId":483,"canonicalUrl":484,"publisher":408,"sourceType":421,"publicationDate":485,"lastChecked":19},{"title":457,"canonicalId":406,"canonicalUrl":458,"publisher":408,"sourceType":409,"publicationDate":410,"lastChecked":19},{"title":488,"canonicalId":489,"canonicalUrl":490,"publisher":491,"sourceType":421,"publicationDate":492,"lastChecked":19},{"claimId":62,"exactClaim":696,"outcome":697,"population":698,"verdict":625,"evidenceLevel":195,"rationale":699,"safetyStatus":669,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":700,"sources":701},"Detecting Candida or reporting its relative abundance in a stool sample establishes that Candida is causing chronic gastrointestinal or multisystem symptoms in an immunocompetent person.","valid causal attribution of chronic gastrointestinal or multisystem symptoms to intestinal Candida","immunocompetent adolescents and adults with chronic gastrointestinal and/or nonspecific extraintestinal symptoms who receive a stool culture, sequencing, or commercial microbiome result reporting Candida","The systematic review found intestinal Candida colonization common in healthy immunocompetent adults and found no epidemiologic or therapeutic evidence for a broad Candida syndrome. Current CDC and IDSA frameworks require disease- and site-specific clinical interpretation rather than equating organism presence with disease. The 2025 international consensus finds clinical usefulness of routine microbiome profiling insufficient, and a 2026 blinded laboratory comparison of seven consumer stool services found major within- and between-provider discrepancies. Stool detection can show that fungal material was measured by that method; it does not establish tissue invasion, a symptom cause, a broad syndrome, or which intervention would improve the person's symptoms.",[],[702,703,704,705,706],{"title":449,"canonicalId":450,"canonicalUrl":451,"publisher":452,"sourceType":453,"publicationDate":454,"lastChecked":19},{"title":457,"canonicalId":406,"canonicalUrl":458,"publisher":408,"sourceType":409,"publicationDate":410,"lastChecked":19},{"title":417,"canonicalId":418,"canonicalUrl":419,"publisher":420,"sourceType":421,"publicationDate":422,"lastChecked":19},{"title":467,"canonicalId":468,"canonicalUrl":469,"publisher":470,"sourceType":421,"publicationDate":471,"lastChecked":19},{"title":474,"canonicalId":475,"canonicalUrl":476,"publisher":477,"sourceType":478,"publicationDate":479,"lastChecked":19},{"claimId":63,"exactClaim":708,"outcome":709,"population":710,"verdict":625,"evidenceLevel":195,"rationale":711,"safetyStatus":669,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":712,"sources":713},"A Candida antigen, anti-Candida antibody, beta-D-glucan, or blood PCR result used outside its defined invasive-disease population independently establishes a chronic broad Candida-overgrowth explanation for nonspecific symptoms.","valid diagnosis of a chronic broad Candida-overgrowth syndrome from an invasive-fungal-disease assay","immunocompetent adolescents and adults with chronic nonspecific symptoms but without a clinical presentation or risk context suggesting invasive candidiasis","IDSA evaluates these nonculture assays only as adjuncts to culture in selected patients with suspected invasive candidiasis. The guideline documents population-dependent performance, false positives, incomplete standardization, and that beta-D-glucan is not specific for Candida. Those invasive-disease data do not validate the assays for a chronic multisystem overgrowth syndrome in a low-risk outpatient population. The FDA also distinguishes measuring an analyte from clinical validity and advises consumers to establish the intended use and limitations before acting on a direct-access result.",[],[714,715,716],{"title":417,"canonicalId":418,"canonicalUrl":419,"publisher":420,"sourceType":421,"publicationDate":422,"lastChecked":19},{"title":461,"canonicalId":406,"canonicalUrl":462,"publisher":463,"sourceType":409,"publicationDate":464,"lastChecked":19},{"title":449,"canonicalId":450,"canonicalUrl":451,"publisher":452,"sourceType":453,"publicationDate":454,"lastChecked":19},{"claimId":64,"exactClaim":718,"outcome":719,"population":720,"verdict":667,"evidenceLevel":204,"rationale":721,"safetyStatus":669,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":722,"sources":723},"Using a direct-to-consumer stool microbiome report to label intestinal Candida overgrowth and choose an antifungal, restrictive diet, or supplement produces validated clinical benefit for people with chronic nonspecific symptoms.","accurate actionable diagnosis and improvement in patient-important symptoms from report-directed management","adolescents and adults with chronic gastrointestinal and/or nonspecific extraintestinal symptoms considering or using direct-to-consumer stool microbiome testing","The international consensus concludes that evidence for microbiome testing's clinical applicability is limited, discourages patient-requested testing without a clinical recommendation, and does not support widespread routine use. The 2026 NIST-led comparison directly demonstrates major analytical discrepancies across seven services and conflicting reports from identical material, but it does not test every product or a Candida-specific clinical endpoint. FDA guidance explains that direct-access tests vary in evidentiary support and that analytical measurement is distinct from clinical validity. Acting as though such a report proves the diagnosis can add test and supplement costs, restrictive or otherwise unwarranted changes, antifungal exposure, and delayed assessment of the symptoms' actual causes; no identified controlled evidence shows that Candida-labelled report-directed care improves those outcomes.",[],[724,725,726,727],{"title":467,"canonicalId":468,"canonicalUrl":469,"publisher":470,"sourceType":421,"publicationDate":471,"lastChecked":19},{"title":474,"canonicalId":475,"canonicalUrl":476,"publisher":477,"sourceType":478,"publicationDate":479,"lastChecked":19},{"title":461,"canonicalId":406,"canonicalUrl":462,"publisher":463,"sourceType":409,"publicationDate":464,"lastChecked":19},{"title":449,"canonicalId":450,"canonicalUrl":451,"publisher":452,"sourceType":453,"publicationDate":454,"lastChecked":19},{"claimId":65,"exactClaim":729,"outcome":730,"population":731,"verdict":602,"evidenceLevel":195,"rationale":732,"safetyStatus":604,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":733,"sources":734},"Before buying or acting on a Candida-related test, reviewing its intended condition, specimen, analytical and clinical validation, applicable population, limitations, and how either result would change care is a constructive way to prepare for clinical evaluation.","informed test selection and interpretation without treating a result as a stand-alone diagnosis or treatment instruction","adolescents and adults with unresolved or chronic symptoms who are considering a home, direct-access, or clinician-ordered Candida-related test","FDA guidance asks consumers to discuss which tests may be useful, understand benefits and limitations, determine whether claims have analytical and clinical validity, and avoid making dietary or health decisions from a result alone. CDC shows that legitimate Candida testing begins with the suspected condition and relevant examination or specimen, while IDSA requires invasive assays to be interpreted in their clinical and risk context. The microbiome consensus adds pre-test clinical information and clinician-led management. A practical discussion can therefore bring the exact report and method, symptom pattern and timing, medications and prior treatments, relevant risk factors, and the question each possible result would answer; evaluation can then target the symptoms and recognized differentials rather than assume a broad Candida cause.",[],[735,736,737,738],{"title":461,"canonicalId":406,"canonicalUrl":462,"publisher":463,"sourceType":409,"publicationDate":464,"lastChecked":19},{"title":457,"canonicalId":406,"canonicalUrl":458,"publisher":408,"sourceType":409,"publicationDate":410,"lastChecked":19},{"title":417,"canonicalId":418,"canonicalUrl":419,"publisher":420,"sourceType":421,"publicationDate":422,"lastChecked":19},{"title":467,"canonicalId":468,"canonicalUrl":469,"publisher":470,"sourceType":421,"publicationDate":471,"lastChecked":19},{"claimId":66,"exactClaim":740,"outcome":741,"population":742,"verdict":667,"evidenceLevel":204,"rationale":743,"safetyStatus":669,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":744,"sources":745},"A restrictive 'Candida diet' that removes sugar, white flour, yeast, fermented foods, dairy, or other broad food groups improves persistent gastrointestinal, fatigue, cognitive, skin, or other nonspecific symptoms by treating intestinal Candida overgrowth.","patient-important improvement in persistent nonspecific symptoms attributable to treatment of intestinal Candida overgrowth","adolescents and adults with persistent gastrointestinal and/or nonspecific extraintestinal symptoms considering a restrictive Candida-labelled diet","No controlled human trial was identified that tests a defined Candida diet against an appropriate comparator and confirms both a relevant Candida condition and patient-important symptom improvement. The older intestinal-colonization review did not establish the broad syndrome or a diet treatment, and the current Mayo review likewise identifies no clinical trial showing that a Candida cleanse treats a known condition. Some people may feel better after replacing highly processed foods with a more nutritious pattern, but that general nutrition effect does not validate a Candida mechanism. Restriction can also add food cost, meal-planning and social burden, poor adherence, and nutritional imbalance without establishing the cause of symptoms; a symptom-directed evaluation and a nutritionally adequate eating pattern remain distinct alternatives to a Candida treatment claim.",[],[746,747],{"title":495,"canonicalId":406,"canonicalUrl":496,"publisher":497,"sourceType":437,"publicationDate":498,"lastChecked":19},{"title":449,"canonicalId":450,"canonicalUrl":451,"publisher":452,"sourceType":453,"publicationDate":454,"lastChecked":19},{"claimId":67,"exactClaim":749,"outcome":750,"population":751,"verdict":667,"evidenceLevel":204,"rationale":752,"safetyStatus":669,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":753,"sources":754},"A low-sugar, low-carbohydrate, yeast-free, or otherwise restrictive Candida diet eradicates or meaningfully reduces intestinal Candida in immunocompetent people and thereby prevents or treats candidiasis.","durable reduction or eradication of clinically relevant intestinal Candida with prevention or resolution of a defined candidiasis outcome","immunocompetent adolescents and adults without a confirmed invasive or site-specific Candida infection who are considering a Candida-labelled diet","Candida can be present in the gastrointestinal tract without establishing disease, and the reviewed evidence does not validate intestinal colonization as the broad syndrome targeted by these diets. No controlled human trial was found showing that a named restrictive diet durably eradicates clinically meaningful intestinal Candida or prevents a defined candidiasis outcome. Food composition, in-vitro growth, animal models, or an unblinded change in stool abundance cannot independently establish patient benefit. The claim also confuses general nutrition with treatment and can lead to prolonged restriction, expense, and delayed assessment of a defined condition.",[],[755,756],{"title":495,"canonicalId":406,"canonicalUrl":496,"publisher":497,"sourceType":437,"publicationDate":498,"lastChecked":19},{"title":449,"canonicalId":450,"canonicalUrl":451,"publisher":452,"sourceType":453,"publicationDate":454,"lastChecked":19},{"claimId":68,"exactClaim":758,"outcome":759,"population":760,"verdict":667,"evidenceLevel":204,"rationale":761,"safetyStatus":669,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":762,"sources":763},"Choosing a diet according to ABO blood type treats intestinal Candida overgrowth or improves broad Candida-attributed symptoms better than the same diet without blood-type matching.","additional Candida-specific clinical benefit caused by matching the dietary pattern to ABO blood type","adolescents and adults considering a blood-type diet for suspected intestinal or broad Candida-related illness","A systematic review screened 1,415 records and found no study establishing health benefit from ABO blood-type diets; the one eligible indirect study concerned MNS blood type and LDL response, not ABO matching or Candida. The Candida-specific search likewise found no trial connecting blood-type matching to a defined Candida outcome. Any benefit from foods within one promoted pattern would not show that ABO matching caused it. Buying, planning, or restricting food by blood group therefore adds burden without validated Candida-specific or matching-specific benefit.",[],[764,765],{"title":501,"canonicalId":502,"canonicalUrl":503,"publisher":504,"sourceType":453,"publicationDate":505,"lastChecked":19},{"title":495,"canonicalId":406,"canonicalUrl":496,"publisher":497,"sourceType":437,"publicationDate":498,"lastChecked":19},{"claimId":69,"exactClaim":767,"outcome":768,"population":769,"verdict":770,"evidenceLevel":213,"rationale":771,"safetyStatus":604,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":772,"sources":773},"Adding a studied oral or vaginal probiotic to conventional antifungal treatment improves short-term clinical or mycological cure in non-pregnant women with laboratory-confirmed uncomplicated vulvovaginal candidiasis.","clinical and mycological cure within 5 to 14 days after treatment","non-pregnant women with symptomatic, laboratory-confirmed uncomplicated vulvovaginal candidiasis, excluding recurrent disease, diabetes, immunosuppression, and mixed vaginal infection","may-help","The 2017 Cochrane review of 10 RCTs and 1,656 participants found low-certainty improvements when probiotics were added to antifungals for short-term clinical cure (RR 1.14, 95% CI 1.05-1.24; 695 participants, 5 studies) and mycological cure (RR 1.06, 95% CI 1.02-1.10; 969 participants, 7 studies). The later six-trial review also reported favorable adjunct findings but contains inconsistent effect reporting and pooled only small subsets. CDC says substantial evidence is absent and ISSVD concludes there is no demonstrated benefit, so the signal is not a general recommendation and cannot be transferred across strains, doses, oral versus vaginal routes, products, or excluded populations. Cost, administration burden, and use alongside rather than instead of established treatment matter.",[],[774,775,776,777],{"title":515,"canonicalId":516,"canonicalUrl":517,"publisher":518,"sourceType":453,"publicationDate":519,"lastChecked":19},{"title":522,"canonicalId":523,"canonicalUrl":524,"publisher":525,"sourceType":453,"publicationDate":526,"lastChecked":19},{"title":482,"canonicalId":483,"canonicalUrl":484,"publisher":408,"sourceType":421,"publicationDate":485,"lastChecked":19},{"title":488,"canonicalId":489,"canonicalUrl":490,"publisher":491,"sourceType":421,"publicationDate":492,"lastChecked":19},{"claimId":70,"exactClaim":779,"outcome":780,"population":781,"verdict":667,"evidenceLevel":204,"rationale":782,"safetyStatus":604,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":783,"sources":784},"A probiotic taken after or alongside antifungal treatment durably prevents recurrent vulvovaginal candidiasis in women with confirmed recurrent disease.","time to first recurrence and recurrence-free status at 3 to 6 months or longer","women with microbiologically confirmed recurrent vulvovaginal candidiasis after treatment of an acute episode","The Cochrane treatment review excluded women with recurrent VVC and found a very-low-certainty one-month relapse signal in only 388 participants from three studies (RR 0.34, 95% CI 0.17-0.68), with no eligible time-to-first-relapse outcome and no durable long-term cure effect. The 2023 review reports lower recurrence in small heterogeneous trials, including 7.2% versus 35.5% at six months in one study (OR 0.14, 95% CI 0.028-0.70), but mixes populations, strains, routes, co-interventions, and definitions. Current CDC and ISSVD guidance does not endorse probiotics for VVC. Product cost and repeated use are therefore not supported by a reliable durable recurrence estimate for confirmed RVVC.",[],[785,786,787,788],{"title":515,"canonicalId":516,"canonicalUrl":517,"publisher":518,"sourceType":453,"publicationDate":519,"lastChecked":19},{"title":522,"canonicalId":523,"canonicalUrl":524,"publisher":525,"sourceType":453,"publicationDate":526,"lastChecked":19},{"title":482,"canonicalId":483,"canonicalUrl":484,"publisher":408,"sourceType":421,"publicationDate":485,"lastChecked":19},{"title":488,"canonicalId":489,"canonicalUrl":490,"publisher":491,"sourceType":421,"publicationDate":492,"lastChecked":19},{"claimId":71,"exactClaim":790,"outcome":791,"population":792,"verdict":667,"evidenceLevel":204,"rationale":793,"safetyStatus":669,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":794,"sources":795},"A probiotic can replace established antifungal treatment and provide equivalent durable clinical cure for acute vulvovaginal candidiasis.","durable clinical and mycological cure without rescue treatment or excess recurrence","women with symptomatic, laboratory-confirmed acute vulvovaginal candidiasis considering probiotic monotherapy","All ten trials in the 2017 Cochrane review used probiotics as adjuncts rather than validated stand-alone replacements. A 2024 publication reports 96% versus 94% microbiological eradication after three days in 100 women assigned vaginal L. fermentum LF5 or miconazole, with recurrence among initially cured participants of 5/48 versus 8/47 at two weeks (p=0.372). That single-blind, sponsor-funded trial was conducted in 1988-1992, has short follow-up, lacks a prespecified noninferiority framework adequate for equivalence, and has direct manufacturer-related conflicts. It cannot establish durable equivalence or a class effect. CDC states substantial evidence is absent and ISSVD concludes there is no benefit; substituting an unvalidated product can delay effective treatment or evaluation of another cause.",[],[796,797,798,799],{"title":529,"canonicalId":530,"canonicalUrl":531,"publisher":532,"sourceType":445,"publicationDate":533,"lastChecked":19},{"title":515,"canonicalId":516,"canonicalUrl":517,"publisher":518,"sourceType":453,"publicationDate":519,"lastChecked":19},{"title":482,"canonicalId":483,"canonicalUrl":484,"publisher":408,"sourceType":421,"publicationDate":485,"lastChecked":19},{"title":488,"canonicalId":489,"canonicalUrl":490,"publisher":491,"sourceType":421,"publicationDate":492,"lastChecked":19},{"claimId":72,"exactClaim":801,"outcome":802,"population":803,"verdict":667,"evidenceLevel":204,"rationale":804,"safetyStatus":669,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":805,"sources":806},"An oral or vaginal probiotic treats presumed intestinal Candida overgrowth and improves chronic gastrointestinal, fatigue, cognitive, skin, or other broad Candida-attributed symptoms in otherwise stable people.","durable patient-important improvement in chronic nonspecific symptoms attributable to treatment of validated intestinal Candida overgrowth","adolescents and adults with chronic gastrointestinal and/or nonspecific extraintestinal symptoms considering probiotics for presumed broad Candida overgrowth","VVC probiotic trials concern a defined vaginal condition and cannot be extrapolated to intestinal colonization or multisystem symptoms. The intestinal-Candida review did not validate a broad syndrome, and the fermented-food consensus emphasizes that probiotic effects require a defined microorganism and demonstrated benefit rather than a class assumption. The final search found no controlled probiotic trial that confirmed a relevant intestinal Candida condition and improved the broad symptom cluster. Product-to-product variation, recurring cost, adherence burden, and delayed symptom-focused assessment remain important limitations.",[],[807,808,809],{"title":449,"canonicalId":450,"canonicalUrl":451,"publisher":452,"sourceType":453,"publicationDate":454,"lastChecked":19},{"title":508,"canonicalId":509,"canonicalUrl":510,"publisher":511,"sourceType":421,"publicationDate":512,"lastChecked":19},{"title":515,"canonicalId":516,"canonicalUrl":517,"publisher":518,"sourceType":453,"publicationDate":519,"lastChecked":19},{"claimId":73,"exactClaim":811,"outcome":812,"population":813,"verdict":602,"evidenceLevel":195,"rationale":814,"safetyStatus":604,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":815,"sources":816},"Candida can form biofilms in defined device-associated and mucosal infections, but demonstrating this biology in those settings does not establish a hidden intestinal biofilm or broad multisystem Candida syndrome in a person with nonspecific symptoms.","presence and clinical relevance of Candida biofilm in a defined infection, without extrapolation to an unvalidated broad syndrome","people with microbiologically and clinically defined Candida infection, especially device-associated candidiasis, compared with otherwise stable people attributing nonspecific symptoms to an unconfirmed intestinal or whole-body Candida biofilm","CDC catheter guidance and the IDSA candidiasis guideline recognize Candida adherence, extracellular matrix, reduced antimicrobial susceptibility, and the clinical importance of source control in defined device-associated infection. Current biofilm synthesis also describes mucosal and device models. None of these sources validates nonspecific symptoms as a test for an intestinal biofilm or permits device-associated findings to be transferred to a broad outpatient syndrome.",[],[817,818,819],{"title":536,"canonicalId":537,"canonicalUrl":538,"publisher":408,"sourceType":421,"publicationDate":539,"lastChecked":19},{"title":417,"canonicalId":418,"canonicalUrl":419,"publisher":420,"sourceType":421,"publicationDate":422,"lastChecked":19},{"title":542,"canonicalId":543,"canonicalUrl":544,"publisher":545,"sourceType":437,"publicationDate":546,"lastChecked":19},{"claimId":74,"exactClaim":821,"outcome":822,"population":823,"verdict":667,"evidenceLevel":204,"rationale":824,"safetyStatus":669,"evidenceAsOf":19,"lastUpdated":19,"status":670,"changeHistory":825,"sources":826},"Adding a supplement, enzyme, herb, essential-oil constituent, or other product marketed as a Candida 'biofilm disruptor' to antifungal treatment improves symptoms, eradicates infection, or prevents recurrence in people with candidiasis or presumed broad Candida overgrowth.","patient-important symptom improvement, microbiologically confirmed cure, or reduced recurrence attributable to an added marketed biofilm-disrupting product","adolescents and adults with confirmed mucosal candidiasis or with chronic nonspecific symptoms attributed to presumed intestinal or broad Candida overgrowth","The current natural-compound review reports many in vitro biofilm effects and some animal or formulation findings but explicitly identifies major assay, exposure, tolerability, and clinical-translation gaps. Current candidiasis guidance does not convert those laboratory endpoints into a general adjunct recommendation. A laboratory reduction in biomass, viability, MIC, or MBEC is not evidence of symptom benefit, cure, recurrence prevention, or safe self-use.",[],[827,828],{"title":542,"canonicalId":543,"canonicalUrl":544,"publisher":545,"sourceType":437,"publicationDate":546,"lastChecked":19},{"title":417,"canonicalId":418,"canonicalUrl":419,"publisher":420,"sourceType":421,"publicationDate":422,"lastChecked":19},{"claimId":75,"exactClaim":830,"outcome":831,"population":832,"verdict":625,"evidenceLevel":195,"rationale":833,"safetyStatus":669,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":834,"sources":835},"A suspected 'Candida biofilm' explains chronic gastrointestinal, fatigue, cognitive, mood, skin, or other nonspecific symptoms and can be diagnosed from those symptoms, treatment resistance, or a consumer stool result without evidence of a defined Candida infection.","diagnostic validity of a biofilm label as the cause of chronic nonspecific symptoms","otherwise stable adolescents and adults with chronic gastrointestinal or multisystem symptoms but no confirmed site-specific or invasive candidiasis","Recognized candidiasis is defined by a compatible disease at a body site, and biofilm findings are setting-specific. CDC and IDSA evidence about device-associated infection does not validate a symptom list, consumer stool abundance, failed self-treatment, or response to a supplement as a diagnostic method for an intestinal biofilm. Current biofilm research likewise does not provide a validated outpatient diagnostic rule for this proposed broad syndrome.",[],[836,837,838,839],{"title":536,"canonicalId":537,"canonicalUrl":538,"publisher":408,"sourceType":421,"publicationDate":539,"lastChecked":19},{"title":405,"canonicalId":406,"canonicalUrl":407,"publisher":408,"sourceType":409,"publicationDate":410,"lastChecked":19},{"title":417,"canonicalId":418,"canonicalUrl":419,"publisher":420,"sourceType":421,"publicationDate":422,"lastChecked":19},{"title":542,"canonicalId":543,"canonicalUrl":544,"publisher":545,"sourceType":437,"publicationDate":546,"lastChecked":19},{"claimId":76,"exactClaim":841,"outcome":842,"population":843,"verdict":667,"evidenceLevel":204,"rationale":844,"safetyStatus":669,"evidenceAsOf":19,"lastUpdated":19,"status":670,"changeHistory":845,"sources":846},"Starting an antifungal, supplement, or restrictive diet for Candida causes a clinically validated Candida Jarisch-Herxheimer reaction with a predictable mechanism, symptom pattern, timing, and course.","validated incidence, diagnostic criteria, time course, and causal attribution of a Candida-specific treatment reaction","adolescents and adults starting prescription antifungals, non-prescription antimicrobial supplements, or a restrictive diet for confirmed candidiasis or presumed broad Candida overgrowth","CDC guidance defines Jarisch-Herxheimer reaction in the specific context of syphilis treatment and describes an acute febrile syndrome within 24 hours. One 2024 narrative review asserts a Candida die-off mechanism and proposes phytotherapy, but it does not supply a systematic search, controlled human incidence data, validated diagnostic criteria, or a comparative treatment study. Current candidiasis guidelines do not establish a Candida-specific Jarisch-Herxheimer syndrome. The terminology therefore cannot be transferred as if the mechanism and clinical course were proven.",[],[847,848,849],{"title":549,"canonicalId":483,"canonicalUrl":550,"publisher":408,"sourceType":421,"publicationDate":485,"lastChecked":19},{"title":553,"canonicalId":554,"canonicalUrl":555,"publisher":556,"sourceType":437,"publicationDate":557,"lastChecked":19},{"title":417,"canonicalId":418,"canonicalUrl":419,"publisher":420,"sourceType":421,"publicationDate":422,"lastChecked":19},{"claimId":77,"exactClaim":851,"outcome":852,"population":853,"verdict":625,"evidenceLevel":195,"rationale":854,"safetyStatus":669,"evidenceAsOf":19,"lastUpdated":19,"status":605,"changeHistory":855,"sources":856},"New, persistent, or worsening physical or psychological symptoms during an antifungal, supplement, cleanse, or restrictive diet prove that Candida is dying and the intervention is working, so the worsening should be endured or the intervention intensified.","validity of worsening as evidence of Candida treatment efficacy and as a reason to continue or intensify an intervention","adolescents and adults using prescription or non-prescription interventions for confirmed candidiasis or presumed broad Candida overgrowth who develop new, persistent, or worsening symptoms","Treatment effectiveness for defined candidiasis is assessed by the relevant clinical and microbiological outcome, not by nonspecific deterioration. CDC's defined Jarisch-Herxheimer guidance is limited to syphilis and cannot validate a Candida inference. The Candida die-off narrative review supplies no controlled evidence that worsening predicts fungal clearance or benefit. Worsening can overlap with an adverse reaction, progression, an incorrect diagnosis, nutritional or medication effects, or another condition and must never be normalized as proof of healing; exact observable triggers and actions remain locale-safety work.",[],[857,858,859,860],{"title":549,"canonicalId":483,"canonicalUrl":550,"publisher":408,"sourceType":421,"publicationDate":485,"lastChecked":19},{"title":553,"canonicalId":554,"canonicalUrl":555,"publisher":556,"sourceType":437,"publicationDate":557,"lastChecked":19},{"title":417,"canonicalId":418,"canonicalUrl":419,"publisher":420,"sourceType":421,"publicationDate":422,"lastChecked":19},{"title":405,"canonicalId":406,"canonicalUrl":407,"publisher":408,"sourceType":409,"publicationDate":410,"lastChecked":19},{"claimId":78,"exactClaim":862,"outcome":863,"population":864,"verdict":667,"evidenceLevel":204,"rationale":865,"safetyStatus":604,"evidenceAsOf":19,"lastUpdated":19,"status":670,"changeHistory":866,"sources":867},"Using the label 'Candida die-off,' reporting treatment-related worsening, or participating in a die-off journey, without an observable disclosure or sign of acute psychological danger, is sufficient on its own to predict an acute crisis and trigger condition-specific crisis routing.","validity of the die-off label or worsening alone as a predictor and triage criterion for acute psychological crisis","adolescents and adults reporting Candida-attributed worsening during an antifungal, supplement, cleanse, or restrictive diet","The reviewed die-off narrative includes psychological and physical worsening claims but provides no validated prognostic or triage evidence. Broader recurrent-urogenital literature documents group-level distress but does not validate a disease or journey label alone as a predictor of imminent harm. This boundary avoids a global alarm while preserving the importance of responding to an actual disclosure or observable sign; the exact locale trigger, care tier, resource, action, and expiry belong only to todos 055 and 056.",[],[868,869],{"title":553,"canonicalId":554,"canonicalUrl":555,"publisher":556,"sourceType":437,"publicationDate":557,"lastChecked":19},{"title":560,"canonicalId":561,"canonicalUrl":562,"publisher":563,"sourceType":437,"publicationDate":564,"lastChecked":19},[871,885,896,909],{"safetyId":872,"observableTrigger":873,"careTier":874,"action":875,"applicablePopulations":876,"excludedPopulations":878,"locale":6,"checkedAt":19,"expiresAt":881,"sources":882},"us-candida-supplement-review-routine","Before starting a dietary supplement marketed for Candida, biofilms, die-off, gut health, or probiotic effects, the person takes a prescription or over-the-counter medicine, uses another supplement, is pregnant or breastfeeding, is a child, or has planned surgery or a recent change in health.","routine","Ask a physician, pharmacist, registered dietitian, or other qualified health professional to review the exact product label, full medicine and supplement list, health conditions, and planned surgery before use.",[877],"people in the United States considering an ingestible dietary supplement marketed for a Candida-related purpose who meet at least one listed trigger",[879,880],"people considering a conventional food rather than a dietary supplement","users with a serious reaction or acute crisis, who need the applicable faster route","2027-01-15",[883,884],{"title":567,"canonicalId":568,"canonicalUrl":569,"publisher":570,"sourceType":409,"publicationDate":571,"lastChecked":19},{"title":574,"canonicalId":575,"canonicalUrl":576,"publisher":570,"sourceType":409,"publicationDate":571,"lastChecked":19},{"safetyId":886,"observableTrigger":887,"careTier":874,"action":888,"applicablePopulations":889,"excludedPopulations":891,"locale":6,"checkedAt":19,"expiresAt":881,"sources":894},"us-probiotic-high-risk-review-routine","Before starting a probiotic product, the intended user is severely ill, immunocompromised, currently in intensive care, has a central venous catheter, receives enteral or parenteral nutrition, or is a premature infant.","Do not self-start the probiotic for a Candida-related purpose; ask the treating clinician to weigh the exact strain, product, indication, and risks against any expected benefit.",[890],"people in the United States considering a probiotic for an intended user with at least one listed high-risk condition or exposure",[892,893],"healthy people without a listed high-risk condition or exposure","people with a current serious reaction or medical emergency",[895],{"title":585,"canonicalId":586,"canonicalUrl":587,"publisher":588,"sourceType":437,"publicationDate":589,"lastChecked":19},{"safetyId":897,"observableTrigger":898,"careTier":899,"action":900,"applicablePopulations":901,"excludedPopulations":903,"locale":6,"checkedAt":19,"expiresAt":881,"sources":906},"us-candida-supplement-serious-reaction-prompt","While using a dietary supplement marketed for a Candida-related purpose, the person develops throat, lip, or tongue swelling; wheezing; fainting; chest pain; shortness of breath; severe persistent vomiting, diarrhea, or abdominal pain; blood in urine, stool, vomit, or sputum; yellow skin or eyes; or slurred speech, one-sided weakness, or sudden vision loss.","prompt","Stop using the supplement and seek immediate medical care; after immediate care is addressed, report the suspected reaction through the FDA Safety Reporting Portal.",[902],"people in the United States using an ingestible dietary supplement marketed for a Candida, biofilm, die-off, gut-health, or probiotic purpose who develop a listed serious reaction",[904,905],"people with mild self-limited symptoms not included in the FDA serious-reaction list","people not using a dietary supplement",[907,908],{"title":567,"canonicalId":568,"canonicalUrl":569,"publisher":570,"sourceType":409,"publicationDate":571,"lastChecked":19},{"title":579,"canonicalId":580,"canonicalUrl":581,"publisher":570,"sourceType":409,"publicationDate":582,"lastChecked":19},{"safetyId":910,"observableTrigger":911,"careTier":912,"action":913,"applicablePopulations":914,"excludedPopulations":916,"locale":6,"checkedAt":19,"expiresAt":918,"sources":919},"us-broad-candida-acute-crisis-emergency","A person describing Candida die-off or worsening during a Candida-labelled diet, supplement, probiotic, or antifungal says they are thinking about suicide, cannot stay safe, or are in acute emotional crisis.","emergency","Call or text 988, or use 988 Lifeline chat, now for free, confidential crisis support available 24 hours a day.",[915],"people in the United States who disclose the observable crisis trigger while discussing self-labelled Candida die-off or treatment-related worsening",[917],"people who use a die-off label or report worsening but do not disclose suicidal thoughts, inability to stay safe, or acute emotional crisis","2026-10-15",[920],{"title":592,"canonicalId":593,"canonicalUrl":594,"publisher":592,"sourceType":595,"publicationDate":596,"lastChecked":19},[922,925,928],{"rel":923,"hreflang":6,"href":924},"alternate","https://candipedia.org/en/research/evidence/broad-candida-claims/",{"rel":923,"hreflang":926,"href":927},"pl-PL","https://candipedia.org/pl/research/dowody/twierdzenia-o-candidzie/",{"rel":923,"hreflang":929,"href":924},"x-default",1784685064834]